Communiqués Annexin Pharmaceuticals AB

Actions

ANNX

SE0025159387

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
12,65 ^SEK	+2,85%		+3,27%	-36,11%

21/07	Annexin Pharmaceuticals fait le point sur les neuf patients traités dans le cadre de l'étude NEXUS	CI
16/07	Calendrier du jeudi 16 juillet	FW

Communiqués

21/07	Annexin updates on nine patients treated in NEXUS study	AQ
03/07	Annexin's rights issue 98 percent subscribed	AQ
23/06	Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO	AQ
15/06	The subscription period in Annexin Pharmaceuticals’ rights issue begins today	AQ
10/06	Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue	AQ
05/06	Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10	AQ
03/06	Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million	AQ
21/05	Annexin investigates a three-day ANXV treatment regimen in patients with RVO	AQ
11/05	Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study	AQ
24/04	Annexin Pharmaceuticals (Q1 review): Study on track	AQ
22/04	Annexin accelerates patient recruitment – five patients treated	AQ
13/04	Annexin Pharmaceuticals : secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026	PU
06/02	Annexin Pharmaceuticals (Q4 review): Phase II study away, with positive initial results	AQ
04/02	Favourable findings in Annexin’s ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion	AQ
29/01	Annexin engages Pareto Securities as liquidity provider	AQ
19/12	Annexin has laid the foundation for continued clinical development	AQ
18/12	Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion	AQ
09/12	Annexin advances phase IIa study by initiating patient treatment	AQ
05/12	First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO	AQ
23/10/25	Annexin's Q3: Establishment of Medical Advisory Board and focus on ophthalmology	AQ
15/10/25	Annexin Pharmaceuticals selected to present at the Eyecelerator conference and meets with the Medical Advisory Board in Orlando	AQ
18/09/25	Annexin strengthens operations with Medical Advisory Board	AQ
16/09/25	Annexin appoints world-leading ophthalmology experts to Medical Advisory Board	AQ
13/08/25	Annexin gets green light for phase IIa study in diabetic retinopathy	AQ
07/08/25	Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO	AQ